Metagenomi Inc (MGX)

$1.61 -0.04 (-2.42%)
Market Cap 61.93M
Revenue (ttm) 52.30M
Net Income (ttm) -78.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -149.25%
Debt to Equity Ratio 0.00
Volume 335,800
Avg Vol 638,106
Day's Range N/A - N/A
Shares Out 37.53M
Stochastic %K 17%
Beta 0.49
Analysts Strong Sell
Price Target $9.33

Company Profile

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. Its genome editing toolbox includes nuclease-based genome editing, base editors, RNA-mediated integration, including prime editing, and DNA-mediated integration, such CRISPR-associated transposases. The company has a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop and commercialize investigational medic...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 871 4880
Address:
5959 Horton Street, 7th Floor, EmeryVille, United States
topstockalerts
topstockalerts Dec. 16 at 1:44 AM
After Hours Top Gainers PT2 $MGX $KAVL $QURE $ORGO $HCWB
0 · Reply
Dani_G_German
Dani_G_German Dec. 11 at 12:05 AM
$MGX any ideas as to why insiders in small quantities?
0 · Reply
stephllllll
stephllllll Dec. 8 at 4:57 PM
$MGX Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference. That's today.
1 · Reply
I_am_retail_investor
I_am_retail_investor Dec. 4 at 2:02 AM
$MGX - volume up, price up !
0 · Reply
d_risk
d_risk Nov. 12 at 4:31 PM
$MGX - Metagenomi Inc. Common Stock - 10Q - Updated Risk Factors MGX’s updated 10-Q risk factors stress heightened risks from third-party collaborations, expanded financial and operational uncertainties, new organizational change risks, increased challenges in IP protection and patent law, regulatory and clinical trial complexities, and potential setbacks from limited resources, leadership changes, and trademark vulnerabilities. #Biotechnology #ClinicalTrials #OperationalUncertainty #RegulatoryRisk #IntellectualProperty 🟢 Added 🟠 Removed https://d-risk.ai/MGX/10-Q/2025-11-12
0 · Reply
JacksonHole
JacksonHole Nov. 12 at 2:34 PM
$MGX nice open just kidding somebody didn’t like what they heard
1 · Reply
Koukla17
Koukla17 Nov. 12 at 12:48 AM
$MGX reducing the workforce by 25% 💪 streamlining MgX001 💪 cash runway until Q4 2027 ! Ionis has 2.5 billion in cash ! Letssssssss gooooo !
0 · Reply
Koukla17
Koukla17 Nov. 12 at 12:43 AM
$MGX $$$100 $TOCK .
0 · Reply
ZippedCookie
ZippedCookie Nov. 11 at 11:26 PM
$MGX a lot of analyst on the call today 👀
1 · Reply
DARKP00L
DARKP00L Nov. 11 at 9:24 PM
$MGX 16:06 on Nov. 11 2025 Metagenomi Promotes Jian Irish To CEO, Appoints Willard Dere Board Chair #tradeideas
0 · Reply
Latest News on MGX
Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference

Dec 1, 2025, 7:00 AM EST - 14 days ago

Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference

Metagenomi to Present at Jefferies Global Healthcare Conference in London

Nov 17, 2025, 8:00 AM EST - 4 weeks ago

Metagenomi to Present at Jefferies Global Healthcare Conference in London

Metagenomi Prioritizes Hemophilia A Program, Lays Off 25% Workforce

Nov 12, 2025, 12:09 PM EST - 4 weeks ago

Metagenomi Prioritizes Hemophilia A Program, Lays Off 25% Workforce

Metagenomi Reports Third Quarter 2025 Financial Results and Announces Strategic Pipeline Prioritization and Leadership Updates

Nov 11, 2025, 4:02 PM EST - 4 weeks ago

Metagenomi Reports Third Quarter 2025 Financial Results and Announces Strategic Pipeline Prioritization and Leadership Updates

Metagenomi Presents New Preclinical Data from MGX-001 Hemophilia A Program Supporting Advancement into Clinical Development

Nov 11, 2025, 4:01 PM EST - 4 weeks ago

Metagenomi Presents New Preclinical Data from MGX-001 Hemophilia A Program Supporting Advancement into Clinical Development

Metagenomi taps Amazon's custom chips to develop gene-editing tools

Oct 22, 2025, 10:02 AM EDT - 7 weeks ago

Metagenomi taps Amazon's custom chips to develop gene-editing tools

AMZN

Metagenomi Reports Business Updates and Second Quarter 2025 Financial Results

Aug 12, 2025, 4:05 PM EDT - 4 months ago

Metagenomi Reports Business Updates and Second Quarter 2025 Financial Results

Metagenomi Appoints Laurence Reid, PhD to its Board of Directors

Aug 11, 2025, 4:05 PM EDT - 4 months ago

Metagenomi Appoints Laurence Reid, PhD to its Board of Directors

KALV

Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025

May 14, 2025, 6:00 AM EDT - 7 months ago

Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025

Metagenomi Reports Business Updates and First Quarter 2025 Financial Results

May 13, 2025, 4:30 PM EDT - 7 months ago

Metagenomi Reports Business Updates and First Quarter 2025 Financial Results

Metagenomi to Present at Upcoming Scientific Meetings

May 2, 2025, 7:00 AM EDT - 8 months ago

Metagenomi to Present at Upcoming Scientific Meetings

Metagenomi Reports Business Updates and Full Year 2024 Financial Results

Mar 17, 2025, 4:05 PM EDT - 9 months ago

Metagenomi Reports Business Updates and Full Year 2024 Financial Results

Metagenomi Announces Publication in Nature Communications on Large Gene Integration Advances Using Novel, Compact CRISPR-associated transposase (CAST) Systems

Mar 13, 2025, 6:19 AM EDT - 9 months ago

Metagenomi Announces Publication in Nature Communications on Large Gene Integration Advances Using Novel, Compact CRISPR-associated transposase (CAST) Systems

Metagenomi to Present at TD Cowen's 45th Annual Health Care Conference

Feb 11, 2025, 8:55 AM EST - 10 months ago

Metagenomi to Present at TD Cowen's 45th Annual Health Care Conference

Metagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones

Jan 16, 2025, 8:55 AM EST - 11 months ago

Metagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones

Metagenomi Announces New Appointment to its Board of Directors

Jan 15, 2025, 8:55 AM EST - 11 months ago

Metagenomi Announces New Appointment to its Board of Directors

Metagenomi to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 8, 2025, 4:05 PM EST - 1 year ago

Metagenomi to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Metagenomi Presents Highly Specific and Efficient Genome Editing Tools at Nature Conference “RNA at the Bench and Bedside IV”

Dec 11, 2024, 6:30 PM EST - 1 year ago

Metagenomi Presents Highly Specific and Efficient Genome Editing Tools at Nature Conference “RNA at the Bench and Bedside IV”

Metagenomi Presents Updated Preclinical Data in Hemophilia A at American Society of Hematology (ASH) 66th Annual Meeting

Dec 9, 2024, 9:16 PM EST - 1 year ago

Metagenomi Presents Updated Preclinical Data in Hemophilia A at American Society of Hematology (ASH) 66th Annual Meeting

Metagenomi, Inc. Is Being Sued For Violating Securities Laws And Shareholders With Losses Are Urged To Contact The Schall Law Firm

Nov 25, 2024, 11:30 AM EST - 1 year ago

Metagenomi, Inc. Is Being Sued For Violating Securities Laws And Shareholders With Losses Are Urged To Contact The Schall Law Firm

FINAL DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Metagenomi

Nov 25, 2024, 9:56 AM EST - 1 year ago

FINAL DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Metagenomi

MGX Deadline: Rosen Law Firm Urges Metagenomi, Inc. (NASDAQ: MGX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Nov 24, 2024, 9:37 AM EST - 1 year ago

MGX Deadline: Rosen Law Firm Urges Metagenomi, Inc. (NASDAQ: MGX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Metagenomi, Inc. Is Being Sued For Violating Securities Laws And Affected Stockholders Are Urged To Assist The Schall Law Firm

Nov 23, 2024, 5:15 PM EST - 1 year ago

Metagenomi, Inc. Is Being Sued For Violating Securities Laws And Affected Stockholders Are Urged To Assist The Schall Law Firm

MGX Deadline: MGX Investors Have Opportunity to Lead Metagenomi, Inc. Securities Lawsuit

Nov 23, 2024, 1:00 PM EST - 1 year ago

MGX Deadline: MGX Investors Have Opportunity to Lead Metagenomi, Inc. Securities Lawsuit

DEADLINE NEXT WEEK: Berger Montague Advises Metagenomi (NASDAQ: MGX) Investors to Contact the Firm Before November 25, 2024

Nov 22, 2024, 11:59 AM EST - 1 year ago

DEADLINE NEXT WEEK: Berger Montague Advises Metagenomi (NASDAQ: MGX) Investors to Contact the Firm Before November 25, 2024

Metagenomi, Inc. Is Being Sued For Violating Securities Laws And Impacted Shareholders Are Urged To Contact The Schall Law Firm

Nov 21, 2024, 12:00 PM EST - 1 year ago

Metagenomi, Inc. Is Being Sued For Violating Securities Laws And Impacted Shareholders Are Urged To Contact The Schall Law Firm

Shareholders of Metagenomi, Inc. Should Contact The Gross Law Firm Before November 25, 2024 to Discuss Your Rights – MGX

Nov 20, 2024, 12:41 PM EST - 1 year ago

Shareholders of Metagenomi, Inc. Should Contact The Gross Law Firm Before November 25, 2024 to Discuss Your Rights – MGX

The Schall Law Firm Invites Investor Participation In A Fraud Case Against Metagenomi Inc

Nov 20, 2024, 11:00 AM EST - 1 year ago

The Schall Law Firm Invites Investor Participation In A Fraud Case Against Metagenomi Inc

The Schall Law Firm Invites Investors To Join A Fraud Case Against Metagenomi Inc

Nov 18, 2024, 1:30 PM EST - 1 year ago

The Schall Law Firm Invites Investors To Join A Fraud Case Against Metagenomi Inc

Metagenomi, Inc. Is Being Sued For Violating Securities Laws And Shareholders With Losses Are Encouraged To Contact The Schall Law Firm

Nov 17, 2024, 3:00 PM EST - 1 year ago

Metagenomi, Inc. Is Being Sued For Violating Securities Laws And Shareholders With Losses Are Encouraged To Contact The Schall Law Firm

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Metagenomi

Nov 14, 2024, 9:18 PM EST - 1 year ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Metagenomi

Metagenomi, Inc. Is Being Sued For Violating Securities Regulations And Shareholders With Losses Are Urged To Help The Schall Law Firm

Nov 13, 2024, 1:15 PM EST - 1 year ago

Metagenomi, Inc. Is Being Sued For Violating Securities Regulations And Shareholders With Losses Are Urged To Help The Schall Law Firm

topstockalerts
topstockalerts Dec. 16 at 1:44 AM
After Hours Top Gainers PT2 $MGX $KAVL $QURE $ORGO $HCWB
0 · Reply
Dani_G_German
Dani_G_German Dec. 11 at 12:05 AM
$MGX any ideas as to why insiders in small quantities?
0 · Reply
stephllllll
stephllllll Dec. 8 at 4:57 PM
$MGX Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference. That's today.
1 · Reply
I_am_retail_investor
I_am_retail_investor Dec. 4 at 2:02 AM
$MGX - volume up, price up !
0 · Reply
d_risk
d_risk Nov. 12 at 4:31 PM
$MGX - Metagenomi Inc. Common Stock - 10Q - Updated Risk Factors MGX’s updated 10-Q risk factors stress heightened risks from third-party collaborations, expanded financial and operational uncertainties, new organizational change risks, increased challenges in IP protection and patent law, regulatory and clinical trial complexities, and potential setbacks from limited resources, leadership changes, and trademark vulnerabilities. #Biotechnology #ClinicalTrials #OperationalUncertainty #RegulatoryRisk #IntellectualProperty 🟢 Added 🟠 Removed https://d-risk.ai/MGX/10-Q/2025-11-12
0 · Reply
JacksonHole
JacksonHole Nov. 12 at 2:34 PM
$MGX nice open just kidding somebody didn’t like what they heard
1 · Reply
Koukla17
Koukla17 Nov. 12 at 12:48 AM
$MGX reducing the workforce by 25% 💪 streamlining MgX001 💪 cash runway until Q4 2027 ! Ionis has 2.5 billion in cash ! Letssssssss gooooo !
0 · Reply
Koukla17
Koukla17 Nov. 12 at 12:43 AM
$MGX $$$100 $TOCK .
0 · Reply
ZippedCookie
ZippedCookie Nov. 11 at 11:26 PM
$MGX a lot of analyst on the call today 👀
1 · Reply
DARKP00L
DARKP00L Nov. 11 at 9:24 PM
$MGX 16:06 on Nov. 11 2025 Metagenomi Promotes Jian Irish To CEO, Appoints Willard Dere Board Chair #tradeideas
0 · Reply
DARKP00L
DARKP00L Nov. 11 at 9:24 PM
$MGX 16:03 on Nov. 11 2025 Metagenomi Presents New Preclinical Data From MGX-001 Hemophilia A Program, Demonstrating Curative FVIII Activity In Non-Human Primates #tradeideas
0 · Reply
DonCorleone77
DonCorleone77 Nov. 11 at 9:12 PM
$MGX Metagenomi reduces workforce by 25%
0 · Reply
RAIK7
RAIK7 Nov. 11 at 9:04 PM
$MGX https://www.stocktitan.net/news/MGX/metagenomi-presents-new-preclinical-data-from-mgx-001-hemophilia-a-tmrumid6va8h.html
0 · Reply
AdiDasRom
AdiDasRom Nov. 7 at 3:12 PM
$MGX
0 · Reply
ThomasTrainTrader
ThomasTrainTrader Nov. 4 at 8:16 PM
$RNAC it’s insane that $MGX is up 10% in the last year and this shit is down 60%. A company with essentially 0 viable assets has a +70% delta on a stock that has a best in class asset
0 · Reply
vinmee
vinmee Nov. 3 at 9:22 PM
$MGX hope amazon buys them
0 · Reply
HarmonyPioneer67
HarmonyPioneer67 Oct. 31 at 3:24 PM
$MGX https://theoutpost.ai/news-story/aws-s-custom-ai-chips-help-metagenomi-slash-costs-in-gene-editing-research-21139/
0 · Reply
HarmonyPioneer67
HarmonyPioneer67 Oct. 31 at 3:21 PM
$MGX https://www.msn.com/en-us/technology/artificial-intelligence/saudi-arabia-uae-pour-over-130-b-into-ai-to-offset-oil-price-risks/ar-AA1PwjFR?ocid=BingNewsSerp
0 · Reply
HarmonyPioneer67
HarmonyPioneer67 Oct. 31 at 2:35 PM
$MGX https://www.reuters.com/business/healthcare-pharmaceuticals/metagenomi-taps-amazons-custom-chips-develop-gene-editing-tools-2025-10-22/
0 · Reply
MikeEhrmantraut
MikeEhrmantraut Oct. 28 at 4:44 PM
$MGX loading up here
0 · Reply
Persent12
Persent12 Oct. 20 at 1:04 PM
$MGX the stock was upgraded this morning to a new #1 on Zack's. Just bought a thousand shares and will buy on any weakness this morning.
0 · Reply
immuz
immuz Oct. 19 at 12:13 PM
$MGX a lot of people thinking this was up big due to the Abu Dhabi MGX, but seems more likely driven by Cathie Wood’s comments on AI in the biotech sector. Maybe ARK is buying up shares.
0 · Reply